Cargando…
VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms. PI3K/AKT/mTOR pathway upregulation is critical for their pathogenesis and is often associated with TSC1/TSC2 inactivation. Although first line mTOR inhibitors are an effective treatment, metastatic PEComas eventually progress...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032946/ https://www.ncbi.nlm.nih.gov/pubmed/33842348 http://dx.doi.org/10.3389/fonc.2021.641376 |
_version_ | 1783676316362473472 |
---|---|
author | Liapi, Aikaterini Mathevet, Patrice Herrera, Fernanda G. Hastir, Delfyne Sarivalasis, Apostolos |
author_facet | Liapi, Aikaterini Mathevet, Patrice Herrera, Fernanda G. Hastir, Delfyne Sarivalasis, Apostolos |
author_sort | Liapi, Aikaterini |
collection | PubMed |
description | Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms. PI3K/AKT/mTOR pathway upregulation is critical for their pathogenesis and is often associated with TSC1/TSC2 inactivation. Although first line mTOR inhibitors are an effective treatment, metastatic PEComas eventually progress. A 53-year-old woman presented a 4-month history of post-menopausal vaginal bleeding. Clinical and radiological examination detected a uterine mass and a single S1 bone lesion. The patient underwent a radical hysterectomy and bone biopsy. The anatomopathological evaluation concluded to an oligo-metastatic uterine PEComa. The tumor harbored a heterozygous deletion of 9q34 that contains the TSC1 gene. Concerning the primary lesion, the resection was complete and the single bone metastasis was treated with radiotherapy. Three months later, the patient presented bone, lung and subcutaneous metastatic progression. An everolimus and denosumab treatment was initiated. After 2 years of treatment, a clinically significant bone, lung and subcutaneous progression was detected. Following a literature review of the possible therapeutic options, we initiated a second line treatment by pazopanib. This treatment resulted in regression of the subcutaneous lesions and stability of lung and bone metastases. In this challenging, rare setting, our report suggests single agent, anti-angiogenic, tyrosine kinase inhibitor to be effective as second line treatment of metastatic uterine PEComa progressing on mTOR inhibitors. |
format | Online Article Text |
id | pubmed-8032946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80329462021-04-10 VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature Liapi, Aikaterini Mathevet, Patrice Herrera, Fernanda G. Hastir, Delfyne Sarivalasis, Apostolos Front Oncol Oncology Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms. PI3K/AKT/mTOR pathway upregulation is critical for their pathogenesis and is often associated with TSC1/TSC2 inactivation. Although first line mTOR inhibitors are an effective treatment, metastatic PEComas eventually progress. A 53-year-old woman presented a 4-month history of post-menopausal vaginal bleeding. Clinical and radiological examination detected a uterine mass and a single S1 bone lesion. The patient underwent a radical hysterectomy and bone biopsy. The anatomopathological evaluation concluded to an oligo-metastatic uterine PEComa. The tumor harbored a heterozygous deletion of 9q34 that contains the TSC1 gene. Concerning the primary lesion, the resection was complete and the single bone metastasis was treated with radiotherapy. Three months later, the patient presented bone, lung and subcutaneous metastatic progression. An everolimus and denosumab treatment was initiated. After 2 years of treatment, a clinically significant bone, lung and subcutaneous progression was detected. Following a literature review of the possible therapeutic options, we initiated a second line treatment by pazopanib. This treatment resulted in regression of the subcutaneous lesions and stability of lung and bone metastases. In this challenging, rare setting, our report suggests single agent, anti-angiogenic, tyrosine kinase inhibitor to be effective as second line treatment of metastatic uterine PEComa progressing on mTOR inhibitors. Frontiers Media S.A. 2021-03-26 /pmc/articles/PMC8032946/ /pubmed/33842348 http://dx.doi.org/10.3389/fonc.2021.641376 Text en Copyright © 2021 Liapi, Mathevet, Herrera, Hastir and Sarivalasis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liapi, Aikaterini Mathevet, Patrice Herrera, Fernanda G. Hastir, Delfyne Sarivalasis, Apostolos VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature |
title | VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature |
title_full | VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature |
title_fullStr | VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature |
title_full_unstemmed | VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature |
title_short | VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature |
title_sort | vegfr inhibitors for uterine metastatic perivascular epithelioid tumors (pecoma) resistant to mtor inhibitors. a case report and review of literature |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032946/ https://www.ncbi.nlm.nih.gov/pubmed/33842348 http://dx.doi.org/10.3389/fonc.2021.641376 |
work_keys_str_mv | AT liapiaikaterini vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature AT mathevetpatrice vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature AT herrerafernandag vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature AT hastirdelfyne vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature AT sarivalasisapostolos vegfrinhibitorsforuterinemetastaticperivascularepithelioidtumorspecomaresistanttomtorinhibitorsacasereportandreviewofliterature |